Clinigen Group agrees to buy Link Healthcare for an initial £44.5 million in cash and stock

22 September 2015

UK-based Clinigen Group (AIM: CLIN) on Tuesday said it has agreed to buy Australian firm Link Healthcare, for an initial £44.5 million ($68.7 million) with a maximum of about £100 million to expand its presence in Asia, Africa and Australasia.

The company said the initial payment of £44.5 million will comprise £22.25 million in cash and the allotment of about 3.1 million Clinigen shares. In addition, a deferred payment of up to £55.5 million in cash if earn out targets are achieved.

Clinigen expects the acquisition to immediately add to its earnings and the transaction to close by end-October this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK